Dexmedetomidine for Sedation During Radiological Interventional Procedures

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluation of the role of dexmedetomidine as a sole agent in sedating patients undergoing interventional radiological procedures and measuring its different outcome variables.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Dexmedetomidine in IVRA

NCT05123170

Regional Anesthesia Morbidity

COMPLETED PHASE4

Dexmedetomidine Versus Propofol for Sedation in Stereotactic Brain Biopsy

NCT03375385

Adverse Effects in the Therapeutic Use of Other and Unspecified Agents Primarily Acting on the Respiratory System

COMPLETED PHASE4

Dexmedetomidine Versus Ketamine Versus Midazolam in Endoscopic Procedures

NCT04597268

Sedation and Analgesia

COMPLETED NA

Dexmedetomidine Infusion Effect on Hemodynamic Variables During Craniotomy

NCT04607525

Hemodynamic Instability Supratentorial Neoplasms

COMPLETED PHASE4

Comparison of Outcomes During MRI Sedation With Midazolam-dexmedetomidine Versus Ketamine-dexmedetomidine

NCT02129426

Sedation

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Procedural Sedation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dexmeditomedine

Dexmedetomidine will be initiated at 0.6 mcg/kg/hr and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hr.

Group Type EXPERIMENTAL

Dexmeditomedine

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dexmeditomedine

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Dexmedetomidine at 0.6 mcg/kg/hr then 0.2 to 1 mcg/kg/hr.

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age from 18-65 years old
* ASA physical status of I-II
* Expected procedure lasting at least 30 minutes

Exclusion Criteria

* Unstable cardiac status (life-threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunction and third-degree heart block.
* An alpha2-agonist or antagonist within 14 days before the scheduled procedure.
* patients received an IV opioid within 1 h, or an oral or IM opioid within 4 h of the start of study drug administration.
* Patients who are allergic to Dexmedetomidine or alpha 2-agonists.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No